• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

血液、血清和腹水参数对恶性腹膜间皮瘤或腹膜癌患者的预后意义

Prognostic Significance of Blood, Serum, and Ascites Parameters in Patients with Malignant Peritoneal Mesothelioma or Peritoneal Carcinomatosis.

作者信息

Su Shan-Shan, Zheng Guo-Qi, Yin Wen-Jie, Liang Yu-Fei, Liu Ying-Ying, Song Hui, Sun Ning-Ning, Yang Yu-Xin

机构信息

Department of Gastroenterology, Cangzhou Central Hospital, Cangzhou, Hebei 061001, China.

出版信息

Gastroenterol Res Pract. 2018 Feb 15;2018:2619526. doi: 10.1155/2018/2619526. eCollection 2018.

DOI:10.1155/2018/2619526
PMID:29643915
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5832177/
Abstract

To determine effects of the biochemical and cytological properties of blood, serum, and ascites on survival of patients with malignant peritoneal effusion (MPeE), including malignant peritoneal mesothelioma (MPeM) and peritoneal carcinomatosis (PC), we conducted a retrospective study of patients with MPeE and healthy controls. Potential prognostic factors were identified as follows: age, sex, blood neutrophil-to-lymphocyte ratio (NLR), serum parameters, ascites parameters, serum-ascites albumin gradient, and the ascites-serum LDH ratio. Compared to those of the control group, serum albumin levels were significantly lower, and the NLR and serum LDH levels were significantly higher in the MPeE group. Overall survival (OS) was longer in patients with MPeM compared to that in patients with PC. Compared with patients in the MPeM, patients with PC had higher NLRs, ascites glucose levels, serum-ascites albumin gradients, and serum LDH levels. In contrast, their ascites albumin levels and ascites-serum LDH ratios were lower. Univariate analyses indicated that the NLR, serum LDH levels, ascites LDH levels, ascites coenocyte levels, and the ascites coenocyte-to-monocyte ratios affected the OS. Multivariate analyses identified only serum and ascites LDH levels as independent prognostic factors.

摘要

为了确定血液、血清和腹水的生化及细胞学特性对恶性腹腔积液(MPeE,包括恶性腹膜间皮瘤(MPeM)和腹膜转移癌(PC))患者生存的影响,我们对MPeE患者和健康对照进行了一项回顾性研究。潜在的预后因素确定如下:年龄、性别、血液中性粒细胞与淋巴细胞比值(NLR)、血清参数、腹水参数、血清-腹水白蛋白梯度以及腹水-血清乳酸脱氢酶比值。与对照组相比,MPeE组血清白蛋白水平显著降低,NLR和血清乳酸脱氢酶水平显著升高。MPeM患者的总生存期(OS)比PC患者更长。与MPeM患者相比,PC患者的NLR、腹水葡萄糖水平、血清-腹水白蛋白梯度和血清乳酸脱氢酶水平更高。相反,他们的腹水白蛋白水平和腹水-血清乳酸脱氢酶比值更低。单因素分析表明,NLR、血清乳酸脱氢酶水平、腹水乳酸脱氢酶水平、腹水多核细胞水平以及腹水多核细胞与单核细胞比值影响OS。多因素分析仅确定血清和腹水乳酸脱氢酶水平为独立预后因素。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e237/5832177/e3a2444b4ae4/GRP2018-2619526.006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e237/5832177/1211598af4f7/GRP2018-2619526.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e237/5832177/d569097b5757/GRP2018-2619526.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e237/5832177/f41deeb98943/GRP2018-2619526.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e237/5832177/c5a86715f356/GRP2018-2619526.004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e237/5832177/2bd6fc882f6d/GRP2018-2619526.005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e237/5832177/e3a2444b4ae4/GRP2018-2619526.006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e237/5832177/1211598af4f7/GRP2018-2619526.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e237/5832177/d569097b5757/GRP2018-2619526.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e237/5832177/f41deeb98943/GRP2018-2619526.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e237/5832177/c5a86715f356/GRP2018-2619526.004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e237/5832177/2bd6fc882f6d/GRP2018-2619526.005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e237/5832177/e3a2444b4ae4/GRP2018-2619526.006.jpg

相似文献

1
Prognostic Significance of Blood, Serum, and Ascites Parameters in Patients with Malignant Peritoneal Mesothelioma or Peritoneal Carcinomatosis.血液、血清和腹水参数对恶性腹膜间皮瘤或腹膜癌患者的预后意义
Gastroenterol Res Pract. 2018 Feb 15;2018:2619526. doi: 10.1155/2018/2619526. eCollection 2018.
2
Pretreatment Controlling Nutritional Status Score and Lactate Dehydrogenase as Predictive Markers of Survival in Patients with Malignant Peritoneal Mesothelioma.预处理控制营养状态评分和乳酸脱氢酶作为恶性腹膜间皮瘤患者生存的预测标志物。
Nutr Cancer. 2018 Nov-Dec;70(8):1264-1274. doi: 10.1080/01635581.2018.1560481. Epub 2019 Jan 20.
3
Significance of EGFR and PTEN Expression and PLR and NLR for Predicting the Prognosis of Epithelioid Malignant Peritoneal Mesothelioma.表皮生长因子受体(EGFR)和磷酸酶及张力蛋白同源物(PTEN)表达以及血小板与淋巴细胞比率(PLR)和中性粒细胞与淋巴细胞比率(NLR)对预测上皮样恶性腹膜间皮瘤预后的意义
Gastroenterol Res Pract. 2019 Feb 4;2019:7103915. doi: 10.1155/2019/7103915. eCollection 2019.
4
The role of imaging in diagnosis and management of malignant peritoneal mesothelioma: a systematic review.影像学在恶性腹膜间皮瘤诊断与管理中的作用:一项系统评价
Abdom Radiol (NY). 2022 May;47(5):1725-1740. doi: 10.1007/s00261-022-03464-x. Epub 2022 Mar 7.
5
[Pathological classification of malignant peritoneal mesothelioma and comparative analysis with peritoneal carcinomatosis].[恶性腹膜间皮瘤的病理分类及与腹膜癌病的对比分析]
Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi. 2023 Jul 20;41(7):541-546. doi: 10.3760/cma.j.cn121094-20211203-00597.
6
Are pretreatment neutrophil-lymphocyte ratio and platelet-lymphocyte ratio useful in predicting the outcomes of patients with small-cell lung cancer?治疗前中性粒细胞与淋巴细胞比值及血小板与淋巴细胞比值对预测小细胞肺癌患者的预后是否有用?
Oncotarget. 2017 Jun 6;8(23):37200-37207. doi: 10.18632/oncotarget.16553.
7
Pathophysiology of elevated ascites fluid cholesterol in malignant ascites. Increased ascites to serum relation of proteins and lipoproteins in patients with peritoneal carcinomatosis as compared to patients with cirrhosis of the liver.恶性腹水中腹水液胆固醇升高的病理生理学。与肝硬化患者相比,腹膜癌患者腹水中蛋白质和脂蛋白与血清的关系增加。
J Hepatol. 1992 Mar;14(2-3):244-8. doi: 10.1016/0168-8278(92)90165-l.
8
Survivin expression as an independent predictor of overall survival in malignant peritoneal mesothelioma.生存素表达作为恶性腹膜间皮瘤总生存期的独立预测指标。
Oncol Lett. 2020 Jun;19(6):3871-3880. doi: 10.3892/ol.2020.11505. Epub 2020 Apr 2.
9
[Malignant peritoneal mesothelioma].[恶性腹膜间皮瘤]
Rev Gastroenterol Peru. 2010 Jan-Mar;30(1):82-7.
10
Lysophosphatidic Acid is a Biomarker for Peritoneal Carcinomatosis of Gastric Cancer and Correlates with Poor Prognosis.溶血磷脂酸是胃癌腹膜转移的生物标志物且与预后不良相关。
Genet Test Mol Biomarkers. 2017 Nov;21(11):641-648. doi: 10.1089/gtmb.2017.0060. Epub 2017 Sep 14.

引用本文的文献

1
Prognostic importance of the neutrophil-to-lymphocyte ratio in malignant peritoneal mesothelioma patients receiving cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.接受肿瘤细胞减灭术和腹腔内热化疗的恶性腹膜间皮瘤患者中中性粒细胞与淋巴细胞比值的预后重要性。
BMC Cancer. 2025 Feb 14;25(1):270. doi: 10.1186/s12885-025-13606-1.
2
Targeting Oncometabolites in Peritoneal Cancers: Preclinical Insights and Therapeutic Strategies.靶向腹膜癌中的肿瘤代谢物:临床前见解与治疗策略
Metabolites. 2023 Apr 30;13(5):618. doi: 10.3390/metabo13050618.
3
Metabolic Reprogramming of Ovarian Cancer Spheroids during Adhesion.

本文引用的文献

1
Overview of BioBank Japan follow-up data in 32 diseases.日本生物样本库32种疾病随访数据概述
J Epidemiol. 2017 Mar;27(3S):S22-S28. doi: 10.1016/j.je.2016.12.006. Epub 2017 Feb 10.
2
Pretreatment elevated serum lactate dehydrogenase as a significant prognostic factor in malignant mesothelioma: A meta-analysis.预处理时血清乳酸脱氢酶升高作为恶性间皮瘤的一个重要预后因素:一项荟萃分析。
Medicine (Baltimore). 2016 Dec;95(52):e5706. doi: 10.1097/MD.0000000000005706.
3
Pleural LDH as a prognostic marker in adenocarcinoma lung with malignant pleural effusion.
卵巢癌球体在黏附过程中的代谢重编程
Cancers (Basel). 2022 Mar 9;14(6):1399. doi: 10.3390/cancers14061399.
胸膜乳酸脱氢酶作为伴有恶性胸腔积液的肺腺癌的预后标志物。
Medicine (Baltimore). 2016 Jun;95(26):e3996. doi: 10.1097/MD.0000000000003996.
4
Malignant Peritoneum Mesothelioma with Hepatic Involvement: A Single Institution Experience in 5 Patients and Review of the Literature.伴有肝脏受累的恶性腹膜间皮瘤:单机构5例患者的经验及文献综述
Gastroenterol Res Pract. 2016;2016:6242149. doi: 10.1155/2016/6242149. Epub 2016 Mar 16.
5
Identifying Malignant Pleural Effusion by A Cancer Ratio (Serum LDH: Pleural Fluid ADA Ratio).通过癌症比率(血清乳酸脱氢酶:胸水腺苷脱氨酶比率)识别恶性胸腔积液。
Lung. 2016 Feb;194(1):147-53. doi: 10.1007/s00408-015-9831-6. Epub 2015 Dec 17.
6
CT differentiation of diffuse malignant peritoneal mesothelioma and peritoneal carcinomatosis.弥漫性恶性腹膜间皮瘤与腹膜转移癌的CT鉴别
J Gastroenterol Hepatol. 2016 Apr;31(4):709-15. doi: 10.1111/jgh.13260.
7
Ascitic Fluid Analysis in the Differential Diagnosis of Ascites: Focus on Cirrhotic Ascites.腹水分析在腹水鉴别诊断中的应用:重点关注肝硬化性腹水。
J Clin Transl Hepatol. 2014 Mar;2(1):58-64. doi: 10.14218/JCTH.2013.00010. Epub 2014 Mar 15.
8
Looking up: Recent advances in understanding and treating peritoneal carcinomatosis.抬头看:理解和治疗腹膜癌病的最新进展。
CA Cancer J Clin. 2015 Jul-Aug;65(4):284-98. doi: 10.3322/caac.21277. Epub 2015 May 4.
9
Prognostic value of pretreatment serum lactate dehydrogenase level in patients with solid tumors: a systematic review and meta-analysis.实体瘤患者治疗前血清乳酸脱氢酶水平的预后价值:一项系统评价和荟萃分析。
Sci Rep. 2015 Apr 22;5:9800. doi: 10.1038/srep09800.
10
Guidelines for the diagnosis and treatment of malignant pleural mesothelioma.恶性胸膜间皮瘤诊断与治疗指南。
J Thorac Dis. 2013 Dec;5(6):E254-307. doi: 10.3978/j.issn.2072-1439.2013.11.28.